Preserved SARS-CoV-2 Vaccine Cell-Mediated Immunogenicity in Patients With Inflammatory Bowel Disease on Immune-Modulating Therapies

Brigid S. Boland; Benjamin Goodwin; Zeli Zhang; Nathaniel Bloom; Yu Kato; Jennifer Neill; Helen Le; Tiffani Tysl; Angelina E. Collins; Parambir S. Dulai; Siddharth Singh; Nghia H. Nguyen; Alba Grifoni; Alessandro Sette; Daniela Weiskopf; John T. Chang; Jennifer M. Dan

doi:10.14309/ctg.0000000000000484

Preserved SARS-CoV-2 Vaccine Cell-Mediated Immunogenicity in Patients With Inflammatory Bowel Disease on Immune-Modulating Therapies

Brigid S. Boland^*, Benjamin Goodwin, Zeli Zhang, Nathaniel Bloom, Yu Kato, Jennifer Neill, Helen Le, Tiffani Tysl, Angelina E. Collins, Parambir S. Dulai, Siddharth Singh, Nghia H. Nguyen, Alba Grifoni, Alessandro Sette, Daniela Weiskopf, John T. Chang, Jennifer M. Dan

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

Immune-modulating medications for inflammatory bowel diseases (IBDs) have been associated with suboptimal vaccine responses. There are conflicting data with SARS-CoV-2 vaccination. We therefore assessed SARS-CoV-2 vaccine immunogenicity at 2 weeks after second mRNA vaccination in 29 patients with IBD compared with 12 normal healthy donors. We observed reduced humoral immunity in patients with IBD on infliximab. However, we observed no difference in humoral and cell-mediated immunity in patients with IBD on infliximab with a thiopurine or vedolizumab compared with normal healthy donors. This is the first study to demonstrate comparable cell-mediated immunity with SARS-CoV-2 vaccination in patients with IBD treated with different immune-modulating medications.

Original language	English (US)
Pages (from-to)	E00484
Journal	Clinical and translational gastroenterology
Volume	13
Issue number	4
DOIs	https://doi.org/10.14309/ctg.0000000000000484
State	Published - Apr 28 2022
Externally published	Yes

ASJC Scopus subject areas

Gastroenterology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.14309/ctg.0000000000000484

Cite this

Boland, B. S., Goodwin, B., Zhang, Z., Bloom, N., Kato, Y., Neill, J., Le, H., Tysl, T., Collins, A. E., Dulai, P. S., Singh, S., Nguyen, N. H., Grifoni, A., Sette, A., Weiskopf, D., Chang, J. T., & Dan, J. M. (2022). Preserved SARS-CoV-2 Vaccine Cell-Mediated Immunogenicity in Patients With Inflammatory Bowel Disease on Immune-Modulating Therapies. Clinical and translational gastroenterology, 13(4), E00484. https://doi.org/10.14309/ctg.0000000000000484

@article{0829d63aebae4c87a91e4c28a417698e,

title = "Preserved SARS-CoV-2 Vaccine Cell-Mediated Immunogenicity in Patients With Inflammatory Bowel Disease on Immune-Modulating Therapies",

abstract = "Immune-modulating medications for inflammatory bowel diseases (IBDs) have been associated with suboptimal vaccine responses. There are conflicting data with SARS-CoV-2 vaccination. We therefore assessed SARS-CoV-2 vaccine immunogenicity at 2 weeks after second mRNA vaccination in 29 patients with IBD compared with 12 normal healthy donors. We observed reduced humoral immunity in patients with IBD on infliximab. However, we observed no difference in humoral and cell-mediated immunity in patients with IBD on infliximab with a thiopurine or vedolizumab compared with normal healthy donors. This is the first study to demonstrate comparable cell-mediated immunity with SARS-CoV-2 vaccination in patients with IBD treated with different immune-modulating medications.",

author = "Boland, {Brigid S.} and Benjamin Goodwin and Zeli Zhang and Nathaniel Bloom and Yu Kato and Jennifer Neill and Helen Le and Tiffani Tysl and Collins, {Angelina E.} and Dulai, {Parambir S.} and Siddharth Singh and Nguyen, {Nghia H.} and Alba Grifoni and Alessandro Sette and Daniela Weiskopf and Chang, {John T.} and Dan, {Jennifer M.}",

note = "Funding Information: Potential competing interests: B.S.B. reports consulting fees from Celgene and Takeda and research grants from Prometheus Biosciences and Gilead. A.E.C. reports consulting fees and speaking fees from AbbVie, Bristol Myers Squibb, Janssen, and Takeda. A.S. is a consultant for Gritstone Bio, Flow Pharma, Arcturus Therapeutics, ImmunoScape, CellCarta, Avalia, Moderna, Fortress and Repertoire. ACKNOWLEDGMENTS Funding Information: Financial support: This work was supported by NIH K23 DK123406 (B.S.B.), NIH P30 DK120515 (B.S.B.), NIH T15LM011271 (N.H.N.), NIH 75N9301900065 (D.W., A.S.), NIH U19AI142742 (Shane Crotty), and NIH K08 AI135078 (J.M.D.). Publisher Copyright: {\textcopyright} 2022 Lippincott Williams and Wilkins. All rights reserved.",

year = "2022",

month = apr,

day = "28",

doi = "10.14309/ctg.0000000000000484",

language = "English (US)",

volume = "13",

pages = "E00484",

journal = "Clinical and Translational Gastroenterology",

issn = "2155-384X",

publisher = "Nature Publishing Group",

number = "4",

}

Boland, BS, Goodwin, B, Zhang, Z, Bloom, N, Kato, Y, Neill, J, Le, H, Tysl, T, Collins, AE, Dulai, PS, Singh, S, Nguyen, NH, Grifoni, A, Sette, A, Weiskopf, D, Chang, JT & Dan, JM 2022, 'Preserved SARS-CoV-2 Vaccine Cell-Mediated Immunogenicity in Patients With Inflammatory Bowel Disease on Immune-Modulating Therapies', Clinical and translational gastroenterology, vol. 13, no. 4, pp. E00484. https://doi.org/10.14309/ctg.0000000000000484

TY - JOUR

T1 - Preserved SARS-CoV-2 Vaccine Cell-Mediated Immunogenicity in Patients With Inflammatory Bowel Disease on Immune-Modulating Therapies

AU - Boland, Brigid S.

AU - Goodwin, Benjamin

AU - Zhang, Zeli

AU - Bloom, Nathaniel

AU - Kato, Yu

AU - Neill, Jennifer

AU - Le, Helen

AU - Tysl, Tiffani

AU - Collins, Angelina E.

AU - Dulai, Parambir S.

AU - Singh, Siddharth

AU - Nguyen, Nghia H.

AU - Grifoni, Alba

AU - Sette, Alessandro

AU - Weiskopf, Daniela

AU - Chang, John T.

AU - Dan, Jennifer M.

N1 - Funding Information: Potential competing interests: B.S.B. reports consulting fees from Celgene and Takeda and research grants from Prometheus Biosciences and Gilead. A.E.C. reports consulting fees and speaking fees from AbbVie, Bristol Myers Squibb, Janssen, and Takeda. A.S. is a consultant for Gritstone Bio, Flow Pharma, Arcturus Therapeutics, ImmunoScape, CellCarta, Avalia, Moderna, Fortress and Repertoire. ACKNOWLEDGMENTS Funding Information: Financial support: This work was supported by NIH K23 DK123406 (B.S.B.), NIH P30 DK120515 (B.S.B.), NIH T15LM011271 (N.H.N.), NIH 75N9301900065 (D.W., A.S.), NIH U19AI142742 (Shane Crotty), and NIH K08 AI135078 (J.M.D.). Publisher Copyright: © 2022 Lippincott Williams and Wilkins. All rights reserved.

PY - 2022/4/28

Y1 - 2022/4/28

N2 - Immune-modulating medications for inflammatory bowel diseases (IBDs) have been associated with suboptimal vaccine responses. There are conflicting data with SARS-CoV-2 vaccination. We therefore assessed SARS-CoV-2 vaccine immunogenicity at 2 weeks after second mRNA vaccination in 29 patients with IBD compared with 12 normal healthy donors. We observed reduced humoral immunity in patients with IBD on infliximab. However, we observed no difference in humoral and cell-mediated immunity in patients with IBD on infliximab with a thiopurine or vedolizumab compared with normal healthy donors. This is the first study to demonstrate comparable cell-mediated immunity with SARS-CoV-2 vaccination in patients with IBD treated with different immune-modulating medications.

AB - Immune-modulating medications for inflammatory bowel diseases (IBDs) have been associated with suboptimal vaccine responses. There are conflicting data with SARS-CoV-2 vaccination. We therefore assessed SARS-CoV-2 vaccine immunogenicity at 2 weeks after second mRNA vaccination in 29 patients with IBD compared with 12 normal healthy donors. We observed reduced humoral immunity in patients with IBD on infliximab. However, we observed no difference in humoral and cell-mediated immunity in patients with IBD on infliximab with a thiopurine or vedolizumab compared with normal healthy donors. This is the first study to demonstrate comparable cell-mediated immunity with SARS-CoV-2 vaccination in patients with IBD treated with different immune-modulating medications.

UR - http://www.scopus.com/inward/record.url?scp=85129779164&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85129779164&partnerID=8YFLogxK

U2 - 10.14309/ctg.0000000000000484

DO - 10.14309/ctg.0000000000000484

M3 - Article

C2 - 35347100

AN - SCOPUS:85129779164

SN - 2155-384X

VL - 13

SP - E00484

JO - Clinical and Translational Gastroenterology

JF - Clinical and Translational Gastroenterology

IS - 4

ER -

Preserved SARS-CoV-2 Vaccine Cell-Mediated Immunogenicity in Patients With Inflammatory Bowel Disease on Immune-Modulating Therapies

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this